Tumor Necrosis Factor-α Antibodies (infliximab, Adalimumab and Certolizumab) in Crohn's Disease: Systematic Review and Meta-analysis

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2013 Nov 26

PMID 24273556

Citations 39

Authors

Pawel Kawalec

Alicja Mikrut

Natalia Wisniewska

Andrzej Pilc

Affiliations

Soon will be listed here.

Abstract

Introduction: This meta-analysis compares the effectiveness and safety of tumor necrosis factor α (TNF-α) antibodies (infliximab, adalimumab and certolizumab) with either a placebo or each of them in the treatment of Crohn's disease (CD).

Material And Methods: A systematic review of literature published up to November 2012 was performed and a meta-analysis of identified studies was carried out. We searched the following databases: PubMed, EMBASE, The Cochrane Library and others. Only randomized or clinical controlled trials were included.

Results: Nineteen clinical trials fulfilled the established criteria (5 studies for infliximab vs. placebo, 6 for each adalimumab or certolizumab vs. placebo and 2 comparing infliximab with adalimumab). The results of meta-analysis showed that anti-TNF therapy in patients with CD is safe and statistically significantly more effective when compared with the placebo for induction of remission at week 4 (RB = 1.90, 95% CI: 1.55-2.33, p < 0.00001), maintenance of remission at weeks 20-30 (RB = 1.86, 95% CI: 1.61-2.15, p < 0.00001) and at weeks 48-56 (RB = 2.75, 95% CI: 2.13-3.54, p < 0.00001) in patients who responded to the induction therapy and patients randomized before the induction. Anti-TNF agents were also superior to the placebo in fistula healing (during short-term induction, as well as long-term maintenance) and inducing CR-70 but not CR-100 at week 4. Moreover, the anti-TNF therapy had a significant effect on achieving both CR-70 and CR-100 during long-term maintenance.

Conclusions: Infliximab, adalimumab and certolizumab are effective as both induction and maintenance therapy in moderate to severe Crohn's disease in adults, including patients with fistulas. The safety profile was acceptable.

Citing Articles

Therapeutic potential of : Chemical isolation and validation of ethnomedicinal claims through and assessment of antioxidant and anti-inflammatory properties.

Joshi K, Devkota H, Al-Mutairi K, Sugimura K, Yahara S, Khadka R Heliyon. 2024; 10(19):e38074.

PMID: 39386820 PMC: 11462247. DOI: 10.1016/j.heliyon.2024.e38074.

Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.

Kamal M, Werida R, Radwan M, Askar S, Omran G, El-Mohamdy M Inflammopharmacology. 2024; 32(5):3259-3269.

PMID: 38985232 PMC: 11416362. DOI: 10.1007/s10787-024-01508-w.

Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.

Dubinsky M, Ma C, Griffith J, Crowell M, Neimark E, Kligys K Adv Ther. 2023; 40(9):3896-3911.

PMID: 37368103 PMC: 10427520. DOI: 10.1007/s12325-023-02546-6.

Stem cell transplantation for induction of remission in medically refractory Crohn's disease.

El-Nakeep S, Shawky A, Abbas S, Abdel Latif O Cochrane Database Syst Rev. 2022; 5:CD013070.

PMID: 35556242 PMC: 9099217. DOI: 10.1002/14651858.CD013070.pub2.

Adipose-Derived Stem Cells in the Treatment of Perianal Fistulas in Crohn's Disease: Rationale, Clinical Results and Perspectives.

Buscail E, Le Cosquer G, Gross F, Lebrin M, Bugarel L, Deraison C Int J Mol Sci. 2021; 22(18).

PMID: 34576129 PMC: 8470328. DOI: 10.3390/ijms22189967.

References

Present D, Rutgeerts P, Targan S, Hanauer S, Mayer L, van Hogezand R . Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340(18):1398-405. DOI: 10.1056/NEJM199905063401804. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Schreiber S, Khaliq-Kareemi M, Lawrance I, Thomsen O, Hanauer S, McColm J . Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357(3):239-50. DOI: 10.1056/NEJMoa062897. View

Winter T, Wright J, Ghosh S, Jahnsen J, Innes A, Round P . Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther. 2004; 20(11-12):1337-46. DOI: 10.1111/j.1365-2036.2004.02285.x. View

Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, DHaens G . Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 2011; 61(2):229-34. DOI: 10.1136/gutjnl-2011-300755. View

Hanauer S, Sandborn W, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D . Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130(2):323-33. DOI: 10.1053/j.gastro.2005.11.030. View

Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4. View

Schreiber S, Rutgeerts P, Fedorak R, Khaliq-Kareemi M, Kamm M, Boivin M . A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005; 129(3):807-18. DOI: 10.1053/j.gastro.2005.06.064. View

Sandborn W, Hanauer S, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D . Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56(9):1232-9. PMC: 2701613. DOI: 10.1136/gut.2006.106781. View

10.

Rutgeerts P, DHaens G, Targan S, Vasiliauskas E, Hanauer S, Present D . Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117(4):761-9. DOI: 10.1016/s0016-5085(99)70332-x. View

11.

Sandborn W, Feagan B, Stoinov S, Honiball P, Rutgeerts P, Mason D . Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357(3):228-38. DOI: 10.1056/NEJMoa067594. View

12.

Colombel J, Sandborn W, Rutgeerts P, Enns R, Hanauer S, Panaccione R . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132(1):52-65. DOI: 10.1053/j.gastro.2006.11.041. View

13.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

14.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J . A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess. 2011; 15(6):1-244. PMC: 4781107. DOI: 10.3310/hta15060. View

15.

Rahimi R, Nikfar S, Abdollahi M . Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother. 2006; 61(1):75-80. DOI: 10.1016/j.biopha.2006.06.022. View

16.

Sandborn W, Rutgeerts P, Enns R, Hanauer S, Colombel J, Panaccione R . Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146(12):829-38. DOI: 10.7326/0003-4819-146-12-200706190-00159. View

17.

Ford A, Sandborn W, Khan K, Hanauer S, Talley N, Moayyedi P . Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106(4):644-59, quiz 660. DOI: 10.1038/ajg.2011.73. View

18.

Targan S, Hanauer S, van Deventer S, Mayer L, Present D, Braakman T . A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337(15):1029-35. DOI: 10.1056/NEJM199710093371502. View

19.

Ehteshami-Afshar S, Nikfar S, Rezaie A, Abdollahi M . A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci. 2012; 7(6):1000-12. PMC: 3264992. DOI: 10.5114/aoms.2011.26612. View

20.

Watanabe M, Hibi T, Lomax K, Paulson S, Chao J, Alam M . Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis. 2012; 6(2):160-73. DOI: 10.1016/j.crohns.2011.07.013. View